NCT05706155

Brief Summary

The goal of this clinical trial is to examine the effect plant-based diet, with a partial replacement of animal protein by plant protein, in blood sugar levels and other health risks of people with type 2 diabetes and excessive weight. The plant-based diet will be compared to a standard healthy diet according to guidelines for people with diabetes. Participants will follow a plant-based or a standard healthy diet for 24 weeks and will maintain their habitual levels of physical activity.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
146

participants targeted

Target at P50-P75 for not_applicable type-2-diabetes

Timeline
20mo left

Started Nov 2022

Longer than P75 for not_applicable type-2-diabetes

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress68%
Nov 2022Dec 2027

Study Start

First participant enrolled

November 1, 2022

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 23, 2022

Completed
1 month until next milestone

First Posted

Study publicly available on registry

January 31, 2023

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 30, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2027

Last Updated

January 29, 2026

Status Verified

January 1, 2026

Enrollment Period

5.2 years

First QC Date

December 23, 2022

Last Update Submit

January 26, 2026

Conditions

Keywords

Diabetes MellitusObesityPlant-based DietInsulin Resistance

Outcome Measures

Primary Outcomes (1)

  • Change in Glycated Hemoglobin

    Difference between groups in glycated hemoglobin

    baseline, 12 and 24 weeks

Secondary Outcomes (16)

  • Glycemic Variability

    baseline and 12 weeks

  • Changes in postprandial metabolism

    baseline and 12 weeks

  • Changes in body composition

    Monthly, up to 24 weeks

  • Changes in cardiometabolic outcomes

    baseline and 24 weeks

  • Changes in blood pressure

    baseline, 12 and 24 weeks

  • +11 more secondary outcomes

Study Arms (2)

Control

ACTIVE COMPARATOR

Hypocaloric diet with predominance of animal protein

Behavioral: Control Diet

Intervention

EXPERIMENTAL

Hypocaloric diet with predominance of plant protein

Behavioral: Plant-based Diet

Interventions

Control DietBEHAVIORAL

Hypocaloric diet to achieve a 5% weight loss with macronutrient distribution according to current guidelines for T2D: 50% of energy from carbohydrates, prioritizing those with low glycemic index; 30% from total fats and a maximum of 10% from saturated fats; 20% of energy from proteins, 15% from animal sources and 5% from plant sources. Participants will also receive printed and validated educational material, with recommendations for healthy eating, and will be instructed to maintain their habitual physical activity level.

Control

Hypocaloric diet to achieve a 5% weight loss. The dietary prescription was adapted from the Eat-Lancet Commission report to Brazilian population culture, with 50% of energy from carbohydrates, prioritizing those with a low glycemic index; 30% from total fats and a maximum of 5% from saturated fats; 20% from proteins, 5% from animal sources and 15% from plant sources. Participants in this group will receive printed and validated support material with recommendations for a healthy and plant-based eating, and will be instructed to maintain their habitual physical activity level.

Intervention

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults (≥18 and ≤65 years old)
  • Diagnosis of Type 2 Diabetes;
  • Glycated hemoglobin from 7% to 11%;
  • Overweight or obesity (BMI ≥25 kg/m² and \<40 kg/m²);
  • Use of any hypoglycemic and insulin;
  • Stable weight (maximum variation of approximately 5%) for at least 12 weeks before screening;
  • Not having undergone dietary intervention in the last 6 months;
  • Have the ability to understand and be able to adhere to intervention proposals;
  • Able and willing to provide an informed consent form for written and to comply with the requirements of the study protocol;

You may not qualify if:

  • Type 1 diabetes mellitus;
  • Retinopathy with vision deficit that limits the activities proposed in the interventions;
  • Chronic kidney disease with estimated glomerular filtration \< 30 mL/min per 1.73m²;
  • Liver failure, chronic viral hepatitis;
  • Grade III or IV heart failure
  • Active or progressive neurodegenerative disease;
  • Prior stroke that has caused sequelae;
  • Use of medications that affect glucose metabolism (e.g. corticosteroids or immunosuppressants) or cause weight loss;
  • Chronic treatment with oral or parenteral corticosteroids (\>7 days consecutive treatment) within 4 weeks prior to screening;
  • Treatment with weight-reducing agents (eg, orlistat, sibutramine, topiramate, bupropion, liraglutide, semaglutide) within the last 12 weeks before screening;
  • Treatment with thyroid hormone that was not maintained at a stable dose in last 12 weeks before screening;
  • History of active substance abuse (including alcohol) within the last year;
  • Thyroid Stimulating Hormone (TSH) outside the normal range;
  • Fasting triglycerides ≥ 600 mg/dL;
  • Tumor diagnosed and/or treated (except basal cell skin cancer, carcinoma in situ of the cervix, or prostate cancer in situ) within the last 5 years;
  • +12 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital de Clínicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil

RECRUITING

Related Publications (9)

  • Toumpanakis A, Turnbull T, Alba-Barba I. Effectiveness of plant-based diets in promoting well-being in the management of type 2 diabetes: a systematic review. BMJ Open Diabetes Res Care. 2018 Oct 30;6(1):e000534. doi: 10.1136/bmjdrc-2018-000534. eCollection 2018.

    PMID: 30487971BACKGROUND
  • Willett W, Rockstrom J, Loken B, Springmann M, Lang T, Vermeulen S, Garnett T, Tilman D, DeClerck F, Wood A, Jonell M, Clark M, Gordon LJ, Fanzo J, Hawkes C, Zurayk R, Rivera JA, De Vries W, Majele Sibanda L, Afshin A, Chaudhary A, Herrero M, Agustina R, Branca F, Lartey A, Fan S, Crona B, Fox E, Bignet V, Troell M, Lindahl T, Singh S, Cornell SE, Srinath Reddy K, Narain S, Nishtar S, Murray CJL. Food in the Anthropocene: the EAT-Lancet Commission on healthy diets from sustainable food systems. Lancet. 2019 Feb 2;393(10170):447-492. doi: 10.1016/S0140-6736(18)31788-4. Epub 2019 Jan 16. No abstract available.

    PMID: 30660336BACKGROUND
  • Moulin CC, Tiskievicz F, Zelmanovitz T, de Oliveira J, Azevedo MJ, Gross JL. Use of weighed diet records in the evaluation of diets with different protein contents in patients with type 2 diabetes. Am J Clin Nutr. 1998 May;67(5):853-7. doi: 10.1093/ajcn/67.5.853.

    PMID: 9583841BACKGROUND
  • Tai MM. A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care. 1994 Feb;17(2):152-4. doi: 10.2337/diacare.17.2.152.

    PMID: 8137688BACKGROUND
  • Czerwoniuk D, Fendler W, Walenciak L, Mlynarski W. GlyCulator: a glycemic variability calculation tool for continuous glucose monitoring data. J Diabetes Sci Technol. 2011 Mar 1;5(2):447-51. doi: 10.1177/193229681100500236.

    PMID: 21527118BACKGROUND
  • Wang YP, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. Braz J Psychiatry. 2013 Oct-Dec;35(4):416-31. doi: 10.1590/1516-4446-2012-1048. Epub 2013 Dec 23.

    PMID: 24402217BACKGROUND
  • Sousa TV, Viveiros V, Chai MV, Vicente FL, Jesus G, Carnot MJ, Gordo AC, Ferreira PL. Reliability and validity of the Portuguese version of the Generalized Anxiety Disorder (GAD-7) scale. Health Qual Life Outcomes. 2015 Apr 25;13:50. doi: 10.1186/s12955-015-0244-2.

    PMID: 25908249BACKGROUND
  • Queiroz de Medeiros AC, Campos Pedrosa LF, Hutz CS, Yamamoto ME. Brazilian version of food cravings questionnaires: Psychometric properties and sex differences. Appetite. 2016 Oct 1;105:328-33. doi: 10.1016/j.appet.2016.06.003. Epub 2016 Jun 7.

    PMID: 27288149BACKGROUND
  • Cruz LN, Fleck MP, Oliveira MR, Camey SA, Hoffmann JF, Bagattini AM, Polanczyk CA. Health-related quality of life in Brazil: normative data for the SF-36 in a general population sample in the south of the country. Cien Saude Colet. 2013 Jul;18(7):1911-21. doi: 10.1590/s1413-81232013000700006.

    PMID: 23827895BACKGROUND

MeSH Terms

Conditions

Diabetes Mellitus, Type 2OverweightObesityDiabetes MellitusInsulin Resistance

Interventions

Diet, Plant-Based

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesOvernutritionNutrition DisordersBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsHyperinsulinism

Intervention Hierarchy (Ancestors)

Diet TherapyNutrition TherapyTherapeuticsDietNutritional Physiological PhenomenaDiet, Food, and NutritionPhysiological Phenomena

Study Officials

  • Fernando Gerchman, PhD

    Hospital de Clínicas de Porto Alegre

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Fernando Gerchman, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
The participants and the care providers will not be blinded. People involved in assessing outcomes and with data analysis will be blinded.
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: This is a single center and open label randomized controlled trial, in which participants will be assigned to one of the two different dietary interventions
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 23, 2022

First Posted

January 31, 2023

Study Start

November 1, 2022

Primary Completion (Estimated)

December 30, 2027

Study Completion (Estimated)

December 30, 2027

Last Updated

January 29, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations